Safety of oral versus intravenous hydration during induction therapy with intravenous foscarnet in AIDS patients with cytomegalovirus infections

International Journal of STD and AIDS

Volumn 11, Issue 10, 2000, Pages 640-647

  Cheung, T W ^a   Jayaweera, D T ^b   Pearce, D ^c   Benson, P ^d   Nahass, R ^e   Olson, C ^f   Wool, G M ^g  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

^e UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^f Astra USA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytomegalovirus infection; Foscarnet; Intravenous hydration HIV; Nephrotoxicity; Oral hydration

Indexed keywords

AMPHOTERICIN B; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; ANTIINFLAMMATORY AGENT; ANTIPROTOZOAL AGENT; ANTIVIRUS AGENT; COTRIMOXAZOLE; FOSCARNET; GENTAMICIN; IBUPROFEN; TUBERCULOSTATIC AGENT; VANCOMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DRUG INDUCED DISEASE; FEMALE; FLUID THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDRATION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS INFECTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADMINISTRATION, ORAL; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CREATININE; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FLUID THERAPY; FOSCARNET; HUMANS; INFUSIONS, INTRAVENOUS; MALE; SODIUM CHLORIDE;

EID: 0033792948     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462001914995     Document Type: Article

References (19)

1. Serious cytomegalovirus disease in the acquired immune deficiency syndrome (AIDS): Clinical findings, diagnosis and treatment
2. Cytomegalovirus infection in homosexual men: Relationship to sexual practices, antibody to human immunodeficiency virus and cell mediated immunity
3. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine
4. Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate
5. Foscarnet-ganciclovir cytomegalovirus retinitis trial; 4. Visual outcomes
6. Mortality in patients with acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis
7. Foscarrtet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): A randomized study
8. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects
9. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir
10. Diagnosis and treatment of cytomegalovirus infection
11. Review of toxicity of foscarnet
12. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome
13. Foscarnet nephrotoxicity mechanism, incidence and prevention
14. Individual comparisons by ranking methods
15. Enteropathy associated with the acquired immunodeficiency syndrome
16. Oral versus intravenous hydration during foscarnet maintenance therapy in AIDS patients with cytomegalovirus disease